EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|17|1|89-97

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.17, Iss.1, 2016-12, pp. : 89-97

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status

By  

Current Cancer Drug Targets, Vol. 14, Iss. 2, 2014-02 ,pp. : 217-224

Bentham Science Publishers

Access to resources Recommend Favorite

EGFR as a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-12 ,pp. : 1293-1301

Bentham Science Publishers

Access to resources Recommend Favorite

KRAS status predicts response to cetuximab in mCRC

By  

Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

A Potencial Theranostic Agent for EGF-R Expression Tumors: 177Lu-DOTA-Nimotuzumab

By  

Current Radiopharmaceuticals, Vol. 5, Iss. 4, 2012-10 ,pp. : 318-324

Bentham Science Publishers

Access to resources Recommend Favorite

Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells

By  

Current Drug Targets, Vol. 14, Iss. 10, 2013-09 ,pp. : 1150-1156

Bentham Science Publishers

Access to resources Recommend Favorite